Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.

MLA

Makanga, Dhon Roméo, et al. “Low Number of KIR Ligands in Lymphoma Patients Favors a Good Rituximab-Dependent NK Cell Response.” Oncoimmunology, vol. 10, no. 1, June 2021, p. 1936392. EBSCOhost, https://doi.org/10.1080/2162402X.2021.1936392.

APA

Makanga, D. R., Jullien, M., David, G., Legrand, N., Willem, C., Dubreuil, L., Walencik, A., Touzeau, C., Gastinne, T., Tessoulin, B., Le Gouill, S., Mahé, B., Gagne, K., Chevallier, P., Clemenceau, B., & Retière, C. (2021). Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. Oncoimmunology, 10(1), 1936392. https://doi.org/10.1080/2162402X.2021.1936392

Chicago

Makanga, Dhon Roméo, Maxime Jullien, Gaëlle David, Nolwenn Legrand, Catherine Willem, Léa Dubreuil, Alexandre Walencik, et al. 2021. “Low Number of KIR Ligands in Lymphoma Patients Favors a Good Rituximab-Dependent NK Cell Response.” Oncoimmunology 10 (1): 1936392. doi:10.1080/2162402X.2021.1936392.